Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.25
Bid: 32.00
Ask: 32.50
Change: 0.50 (1.57%)
Spread: 0.50 (1.563%)
Open: 31.75
High: 32.80
Low: 32.25
Prev. Close: 31.75
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading and Dividend Update

14 May 2020 07:00

RNS Number : 8331M
Duke Royalty Limited
14 May 2020
 

14 May 2020

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

 

Trading and Dividend Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, provides the following trading update.

 

Current Trading

Further to our trading update on 2 April 2020, Duke has been working closely with its royalty partners to understand the impact of the Covid-19 pandemic on their businesses and to ensure that they are provided with the necessary support to trade through this challenging period. By design, Duke's long-term capital is structured to be aligned with its royalty partners, their owners and managers through the ups and downs of economic cycles.

Whilst impacts to Duke's portfolio are inevitable during the pandemic, management are pleased with the ongoing resilience demonstrated by the Group's portfolio as a whole. Through its diversified portfolio, Duke naturally has exposure to a range of sectors, some of which are impacted to a greater extent by Covid than others, such as hospitality & leisure. In certain situations where Covid-19 has had the greatest impact, Duke has elected to either accrue, capitalise or equitise its monthly cash payments in the short term with the intention of alleviating the negative cashflow impacts for its royalty partners during this time of unprecedented financial stress.

Nevertheless, cash revenue received in April totalled over £600,000 and this level of monthly cash revenue is expected to be maintained through the quarter ended 30 June 2020 ("Q1 2020"). While this is below the £1 million cash receipts of March, it should be noted that the reduction has not been waived or lost by Duke, rather it has resulted from the restructuring detailed above with the anticipation that the shortfall will be made up in subsequent periods as the pandemic stabilises and trading improves.

Based on the proactive cost cutting measures that were put in place by Duke in March, the Company estimates that its annual operating cost base is currently running at approximately £1.8 million. Therefore, it is pleasing to note that the Company's Q1 2020 cash receipts will likely exceed its entire FY 2021 annual operating cost budget, thereby highlighting the high margin and cash generative nature of Duke's business model.

The Company's liquidity position also remains strong, with cash on hand of over £3 million and additional liquidity of approximately £18 million via its revolving line of credit with Honeycomb Investment Trust. Duke anticipates making additional investments into its existing royalty partners over the coming months, both to provide financial support and to provide acquisition capital in certain circumstances. While it is too early to make any definite forecasts, Duke remains cautiously optimistic that its royalty partners will be able to successfully navigate through this unique period of uncertainty and Duke looks forward to be able to report on a more normalised trading environment in due course.

Dividend

In light of the lower cash receipts expected in the short term, and the likely follow-on investments that Duke intends to make into its existing royalty partners in the coming months, the Company feels it would be prudent to retain cash as much as possible to support its portfolio. To that effect, for the upcoming June quarter, Duke will elect to pay shareholders a scrip dividend instead of its normal cash dividend, with the exact quantum to be announced in the normal timing cycle of mid-June. Since 2017, Duke has paid out more than £12.7 million in cash dividends and intends to revert to the payment of cash dividends when a more normalised trading environment returns. Further timings and details relating to the scrip dividend will be provided in the June announcement.

Neil Johnson, CEO of Duke Royalty, said:

"While we face an unexpected business environment, royalty companies are designed to withstand downside economic shocks. Duke Royalty benefits from both low operating costs and senior security in our investments, while limiting the downside adjustment in any given year.

"Our short-term priority is to support our royalty partners in order to protect our portfolio, while helping the long-term future of each company. Like most lenders in the market, we have made our contribution towards the fight against this virus by way of restructuring some of the repayment terms where necessary. I would like to take this opportunity to thank our royalty partners, some of which have also altered their business to contribute in the quest to overcome Covid-19, for the resilience they have shown in recent weeks.

"Our commitment to our shareholders is also steadfast. Currently, the Board believes cash conservation is prudent, which has been the response of most businesses during this pandemic. However, rewarding shareholders through dividends is a priority, so we will continue the dividend through a scrip arrangement.

"Given the strong financial performance we delivered ahead of the outbreak, I believe we will move out of this extraordinary time having demonstrated the resilience of our model, the benefits of our capital over short dated bank debt, and the strength of our support for our partners in overcoming this unique trading period."

 

***ENDS***

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes / Hugo Evans

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

Newgate Communications (PR)

Elisabeth Cowell/ Ian Silvera/ Megan Kovach

+ +44 (0) 20 3757 6880 dukeroyalty@newgatecomms.com

 

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTGPUMWAUPUGMW
Date   Source Headline
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update
21st Jun 20227:00 amRNSInterim Dividend and Dividend Declaration
1st Jun 20224:25 pmRNSHolding(s) in Company
27th May 20229:08 amRNSDirector / PCA Dealings
26th May 20223:23 pmRNSResult of General Meeting and Issue of Equity
11th May 20227:05 amRNSRaises £20m through Placing and PrimaryBid Offer
10th May 20225:08 pmRNSPrimaryBid Offer
10th May 20224:44 pmRNSPlacing to raise a minimum of £15 million
28th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
20th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
11th Apr 20227:00 amRNSTrading Update
18th Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Mar 20227:00 amRNSIncreased Interim Dividend & Dividend Declaration
2nd Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
25th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Feb 20227:00 amRNSFurther re: Directorate Change
14th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
2nd Feb 20227:00 amRNSDirectorate Changes
1st Feb 202210:02 amRNSReplacement - Trading Update
1st Feb 20227:00 amRNSTrading Update
20th Jan 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
23rd Dec 20212:30 pmRNSHolding(s) in Company
23rd Dec 20217:01 amRNSTrading Update
23rd Dec 20217:00 amRNSFollow-on investment into existing Royalty Partner
22nd Dec 20213:52 pmRNSFollow-on investment into existing Royalty Partner
16th Dec 20217:00 amRNSNew Royalty Agreement
14th Dec 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
7th Dec 20217:00 amRNSEnters into Largest Royalty Agreement To Date
3rd Dec 20217:00 amRNSInterim Results
2nd Dec 20217:00 amRNSCompletion of £4.2 million Follow-On Investment
25th Nov 20217:00 amRNSNotice of Interim Results
29th Oct 20214:03 pmRNSLong Term Incentive Plan Awards
27th Oct 20217:01 amRNSFollow-On Investment into Existing Royalty Partner
27th Oct 20217:00 amRNSHolding(s) in Company
22nd Oct 20214:36 pmRNSResult of Annual General Meeting
16th Sep 20217:01 amRNSInterim Dividend and Dividend Declaration
16th Sep 20217:00 amRNSFinal Results
7th Sep 20217:00 amRNS£2.2m Follow-On Investment into Royalty Partner
2nd Sep 20217:00 amRNSHolding(s) in Company
17th Aug 20217:00 amRNSInvestor Presentation
11th Aug 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20217:00 amRNSNotice of Results and Analyst Presentation
2nd Aug 20217:00 amRNSNew Royalty Agreement
26th Jul 20217:00 amRNSTrading Update
22nd Jul 20217:00 amRNSNew Royalty Agreement
1st Jul 20217:00 amRNSNew Royalty Agreement with Fairmed Healthcare AG
17th Jun 20217:00 amRNSInterim Dividend and Dividend Declaration
10th May 20217:00 amRNSTrading Update
20th Apr 20215:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.